Financial Services » Investing & Securities | MedGen Inc.

MedGen Inc. | Income Statement

Fiscal year is October-September. All values USD Thousands.
2013
2014
2015
2016
2017
Sales/Revenue
242.10
184.10
20.90
-
-
Cost of Goods Sold (COGS) incl. D&A
179.00
123.30
16.10
-
-
Gross Income
63.10
60.80
4.80
-
-
SG&A Expense
114.80
165.60
73.00
170.00
2.70
EBIT
51.70
104.80
68.10
170.00
2.70
Unusual Expense
-
0.90
20.90
190.50
62.90
Non Operating Income/Expense
7.00
-
-
-
-
Interest Expense
-
1,072.20
75.20
199.20
67.60
Pretax Income
44.70
1,177.90
88.00
559.70
7.30
Consolidated Net Income
44.70
1,177.90
134.50
559.70
7.30
Net Income
44.70
1,177.90
134.50
559.70
7.30
Net Income After Extraordinaries
44.70
1,177.90
134.50
559.70
7.30
Net Income Available to Common
44.70
1,177.90
134.50
559.70
7.30
EPS (Basic)
0.00
0.00
0.00
0.00
-
Basic Shares Outstanding
600,788.90
1,326,148.10
1,824,054.90
2,867,815.00
2,867,815.00
EPS (Diluted)
0.00
0.00
0.00
0.00
0.00
Diluted Shares Outstanding
600,788.90
1,326,148.10
3,230,194.90
2,867,815.00
2,867,815.00
EBITDA
51.70
104.80
68.10
170.00
2.70

About MedGen

View Profile
Address
20 Peachtree Court
Holbrook New York 11741
United States
Employees -
Website -
Updated 07/08/2019
MedGen, Inc. (New York) engages in the manufacture, sale, and licensing of healthcare products. Its product portfolio includes SNORenz, SNORenz Night-Time, Sombium, Focamine, Wide Awake, Stem Intense, and Relaxapro. The company was founded in October 1996 and is headquartered in Holbrook, NY.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.